CVA Family Office’s Quest Diagnostics DGX Stock Holding History

CVA Family Office’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.3K	Sell	256 -5	-2%	-$981	﹤0.01%	590
2026 Q1	$51.2K	Buy	261 +117	+81%	+$22.7K	0.01%	590
2025 Q4	$25K	Hold	144	–	–	﹤0.01%	657
2025 Q3	$27.4K	Buy	144 +3	+2%	+$532	﹤0.01%	637
2025 Q2	$25.3K	Sell	141 -23	-14%	-$4K	﹤0.01%	647
2025 Q1	$27.7K	Sell	164 -4	-2%	-$657	﹤0.01%	632
2024 Q4	$25.3K	Buy	168 +35	+26%	+$5.44K	﹤0.01%	636
2024 Q3	$20.6K	Sell	133 -1	-0.7%	-$149	﹤0.01%	652
2024 Q2	$18.3K	Buy	134 +4	+3%	+$548	﹤0.01%	655
2024 Q1	$17.3K	Buy	+130	New	+$16.9K	﹤0.01%	665
2023 Q3	–	Sell	-5	Closed	-$703	–	411
2023 Q2	$703	Buy	+5	New	+$689	﹤0.01%	966
2022 Q3	–	Sell	-45	Closed	-$6K	–	884
2022 Q2	$6K	Hold	45	–	–	﹤0.01%	715
2022 Q1	$6K	Buy	+45	New	+$6.27K	﹤0.01%	744

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

CVA Family Office's DGX Position: Q2 2026 in Review

CVA Family Office reduced its Quest Diagnostics (DGX) stake by 1.9% in Q2 2026, selling an estimated $981 and leaving 256 shares worth $54.3K. The position accounts for ﹤0.01% of the portfolio, ranked #590.

CVA Family Office first reported a position in DGX in Q1 2022 and has held it in 13 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

CVA Family Office held 256 shares of Quest Diagnostics worth $54.3K as of Q2 2026.
CVA Family Office sold 5 Quest Diagnostics shares in Q2 2026, an estimated $981.
Quest Diagnostics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #590 holding.
CVA Family Office first reported a position in Quest Diagnostics in Q1 2022 and has held it in 13 quarters since.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.